The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies released its third quarter earnings, providing an updated snapshot of the company’s financial status and ongoing initiatives.
The company reported that its lead gene therapy candidate, TSHA-102, currently under clinical evaluation for Rett syndrome, continues to exhibit a favorable safety profile. According to Taysha Gene Therapies, TSHA-102 remains generally well tolerated, with no severe treatment-related serious adverse events observed to date.
View post on X Loading...
Earlier this year, Taysha Gene Therapies presented new clinical progress on TSHA-102 for Rett syndrome at a key neurology meeting, as reported in a previous update. The company also discussed TSHA-102 advancements with the neurology community at the CNSAM event, according to company disclosures. These activities have focused attention on the development of TSHA-102 in the clinical setting.